Medicare’s decision not to fund Aduhelm changes landscape for US pharma industry
The decision by the agency responsible for Medicare to restrict coverage of Biogen’s Alzheimer’s drug aducanumab (Aduhelm) to patients enrolled in randomised controlled trials has soured the…
